DARZALEX® — Redefining Approaches in Early-Line Multiple Myeloma Treatment

NEWLY DIAGNOSED, TRANSPLANT-INELIGIBLE MM

DARZALEX® + Rd

(lenalidomide +
dexamethasone)

MAIA TRIAL

DARZALEX® + VMP

(bortezomib + melphalan +
prednisone)

ALCYONE TRIAL

MM=multiple myeloma.

AT FIRST RELAPSE

DARZALEX® + Rd

(lenalidomide +
dexamethasone)

POLLUX TRIAL

DARZALEX® + Vd

(bortezomib +
dexamethasone)

CASTOR TRIAL

AFTER ≥2 PRIOR THERAPIES*

DARZALEX® + Pd

(pomalidomide +
dexamethasone)

*Prior therapies included lenalidomide and a proteasome inhibitor (PI).

EQUULEUS TRIAL

AFTER ≥3 PRIOR THERAPIES

DARZALEX®
Monotherapy

Prior therapies included a PI and an immunomodulatory agent or patients were double-refractory to a PI and an immunomodulatory agent.

SIRIUS TRIAL

DARZALEX® has extensive clinical experience in multiple myeloma1,2

90,000 patients treated worldwide

~90,000 Patients Treated
Worldwide Since Approval2

1530 patients received DARZALEX® in clinical trials

1530 Patients Treated With DARZALEX® in Clinical Trials1

DARZALEX® has 6 registrational trials in MM

6 Registrational Trials in Multiple Myeloma1§

 

As of June 2019. Estimate based on projected patients, calculations on demand, and duration of treatment.

§Includes 4 large, phase 3 clinical trials.

DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma1:

  • in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
  • in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
  • in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
  • in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
  • in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
  • as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent